Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2012 Apr 6;21(6):925–933. doi: 10.1158/1055-9965.EPI-11-1183

Table 1.

Patient information.

Patient
#1 		Age,
M/F2 		Etiology3 T-BIL4 AST5 ALT6 GGTP7 AFP8
1 69 M HCV 1.2 142 286 60 12
2 63 M HCV 0.7 77 73 47 143
3 69 F HCV 0.8 64 57 103 53/103
4 59 M HCV 0.5 83 101 121 24
5 59 M HCV 0.8 102 115 235 12
6 66 M HCV 0.8 99 206 106 40
7 63 M HBV 1.4 58 53 180 17
8 65 F HCV 0.9 35 37 77 13
9 63 F HBV 0.9 57 47 40 6
10 63 M HCV 0.5 48 54 53 15
11 53 M HCV 0.7 157 154 179 96
12 64 M HCV 0.9 133 141 57 96
13 64 M NBNC 0.4 48 69 171 12
14 66 F HBV 1.3 19 14 14 1276
15 50 F HBV NA 38 51 NA 18500
16 NA NA NA NA NA NA NA
1)

Patient pairs. For each patient, HCC and adjacent tissue was obtained.

2)

The gender, Male (M) or female (F) and age of the patient.

3)

The etiology of the cancer. HCV is hepatitis C virus; HBV is hepatitis B Virus, NBNC is non HBV and non HCV liver disease.

4)

Total Bilirubin levels in mg/dL.

5)

Aspartate transaminase in IU/L.

6)

Alanine transaminase in IU/L.

7)

Gamma-glutamyl transpeptidase in IU/L.

8)

Alpha feto protein in ng/mL.